Fulltext
Full text is available in PDF
Official Journal of Research Center for Gastroenterology and Liver Diseases
e-ISSN 1735-3408
p-ISSN 1735-143X
The optimal dose of ribavirin for chronic hepatitis C: From literature evidence to clinical practice
Authors
1Department of Experimental and Clinical Medicine, University Magna Gracia of Catanzaro, Catanzaro, Italy
*Corresponding Author: Ludovico Abenavoli, Department of Experimental and Clinical Medicine, University Magna Gracia, Viale Europa, 88100, Catanzaro, Italy. Tel: +39-09613697113, Fax: +39-0961754220. Email: l.abenavoli@unicz.it
Published online:Apr 30, 2011
Article type:Review Article
Received:Nov 06, 2010
Accepted:Jan 25, 2011
How to Cite:Mazza M, Almasio P, Abenavoli L. The optimal dose of ribavirin for chronic hepatitis C: From literature evidence to clinical practice. Hepat Mon. 2011;11(4):. doi:
Abstract
Approximately 170 million people worldwide are chronically infected by hepatitis C virus (HCV), which can result in progressive hepatic injury and fibrosis, culminating in cirrhosis and end-stage liver disease. The benchmark therapy for untreated HCV patients is a combination of pegylated interferon-alpha (PEG-IFN) and ribavirin (RBV). Several studies have suggested several potential new approaches to improve HCV therapy-optimization of the dose and duration of RBV therapy, accompanied by careful clinical management, is crucial in ensuring the greatest likelihood of a long response to therapy. RBV causes serious side effects, but in clinical practice, there are no alternatives for the treatment of HCV infection. Based on our results, weight-based doses of RBV are advantageous for genotype 1-infected patients, but its success in genotype 2- and 3-infected patients is unknown, particularly for shorter treatment durations.
Keywords: Hepatitis C virus; Ribavirin; dose-response
© 2011 Kowsar M.P.Co. All rights reserved.
Highlights
Copyright
© 2011, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Similar Articles
28
Feb
2013
Commentary on: The optimal Dose of Ribavirin for Chronic Hepatitis C: From Literature Evidence to Clinical Practice
Mortada El-Shabrawi,
Mona Isa
El-Shabrawi M, Isa M. Commentary on: The optimal Dose of Ribavirin for Chronic Hepatitis C: From Literature Evidence to Clinical Practice. Hepat Mon. 2013;13(2):e7867. doi: https://doi.org/10.5812/hepatmon.7867
31
Dec
2008
Optimizing Treatment with Pegylated Interferon-Ribavirin of Genotype 3 Chronic Hepatitis C: More Questions than Answers
Alessio Aghemo,
Roberta D'Ambrosio,
Maria Grazia Rumi,
Massimo Colombo
Aghemo A, D'Ambrosio R, Rumi M, Colombo M. Optimizing Treatment with Pegylated Interferon-Ribavirin of Genotype 3 Chronic Hepatitis C: More Questions than Answers. Hepat Mon. 2008;8(4):. doi:
1
Jan
2015
Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1
Heidar Sharafi,
Seyed Moayed Alavian,
Maryam Keshvari
Sharafi H, Alavian SM, Keshvari M. Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1. Hepat Mon. 2015;15(1):e24955. doi: https://doi.org/10.5812/hepatmon.24955
31
May
2004
Combination Therapy of Interferon-alpha (PDferon B®) and Ribavirin for Chronic Hepatitis C
Seyed Moayed Alavian,
Ali Kabir,
Behzad Hajarizadeh,
Mohsen Nayebpour Pharm,
bashir hajibeigi,
Taher Doroudi
,et al.Alavian SM, Kabir A, Hajarizadeh B, Nayebpour Pharm M, hajibeigi B, et al. Combination Therapy of Interferon-alpha (PDferon B®) and Ribavirin for Chronic Hepatitis C. Hepat Mon. 2004;4(6):e92940. doi:
14
Dec
2013
Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin
Zaigham Abbas,
Ghiasun Nabi Tayyab,
Mustafa Qureshi,
Mohammad Sadik Memon,
Amna Subhan,
Tanzila Shakir
,et al.Abbas Z, Tayyab GN, Qureshi M, Memon MS, Subhan A, et al. Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin. Hepat Mon. 2013;13(12):e14146. doi: https://doi.org/10.5812/hepatmon.14146
More by these authors
Cited by
- Scopus by DOI: 0
Last Update: 3 weeks ago
- Scopus by Title: 15
Last Update: 3 weeks ago
- Scopus by Title (Ref): 15
Last Update: 3 weeks ago
- CrossRef: 0
Last Update: 4 hours ago
- OpenAlex: 0
Last Update: 1 day ago
- OpenCitations: 0
Last Update: 4 days ago
Comments
Number of Comments:0